Loading stock data…
$1.29+0.02 (+1.57%)
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RenovoRx, Inc. in the Healthcare sector is trading at $1.29 with a market capitalization of $99M. Wall Street consensus targets $7.12 (4 analysts), implying a +452.3% move over the next 12 months. The stock is currently 50% below its 52-week high of $2.59, remaining 17.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $909,000↑ | $563,000↑ | $238,000↓ | $266,000↓ | $422,000 |
| Gross Profit | $766,000↑ | $479,000↑ | $210,000↓ | $213,000↓ | $270,000 |
| Operating Income | -$3.35M↑ | -$3.47M↑ | -$3.52M↓ | -$3.20M↓ | -$2.68M |
| Net Income | -$2.91M↑ | -$3.52M↓ | -$2.94M↓ | -$2.91M↓ | -$2.90M |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which i...